• Rationale and Comments

    Glucose-6-phosphate dehydrogenase deficiency testing is recommended upon entry into care or before starting therapy with an oxidant drug only in patients with human immunodeficiency virus (HIV) infection who are predisposed to this genetic disorder that can cause hemolytic anemia. Glucose-6-phosphate dehydrogenase deficiency most frequently occurs in populations of African, Asian, and Mediterranean descent and is most likely to affect HIV-infected patients with one of these racial or ethnic backgrounds.

    Sponsoring Organizations

    • HIV Medicine Association


    • IDSA guideline


    • Infectious disease


    • Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA; Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jan;58(1):1-10.
    • Prchal JT, Gregg XT. Red cell enzymes. American Society of Hematology. 2015 Aug 11;(1):19-23.